A private company using the brain to treat the heart has attracted $113 million in new financing to support a device that the FDA has designated for the expedited access pathway (EAP) program. Minneapolis-based Cvrx Inc. said $93 million of the new funding will come from a completed $57.7 million equity financing and another $35.3 million from the same investors that will be based on operational milestones. The other $20 million will come from a new $20 million debt facility. Read More
